Certified by Founder
Lodge
Rampart Bioscience
start up
United States
- Delhi, California
- 25/10/2023
- Series A
- $85,000,000
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies.
Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Industry Biotechnology Research
- Website https://rampartbio.com/
- LinkedIn https://www.linkedin.com/company/rampart-bioscience/about/
SetSale | $2,000,000 | (Mar 19, 2026)
Raven.io | $20,000,000 | (Mar 19, 2026)
Manifold Security | $8,000,000 | (Mar 19, 2026)
Beautiful.ai | $45,000,000 | (Mar 19, 2026)
xmemory | $4,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)
Obin AI | $7,000,000 | (Mar 19, 2026)
Multiply(US) | $9,500,000 | (Mar 19, 2026)
Respan (formerly Keywords AI) | $5,000,000 | (Mar 19, 2026)
Homaio | $4,135,744 | (Mar 19, 2026)
Foresight(UK) | $25,000,000 | (Mar 19, 2026)
VerbaFlo.AI | $7,000,000 | (Mar 18, 2026)